Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Total Non-Current Liabilities (2019 - 2025)

Historic Total Non-Current Liabilities for Legend Biotech (LEGN) over the last 7 years, with Q3 2025 value amounting to $268.1 million.

  • Legend Biotech's Total Non-Current Liabilities fell 2313.72% to $268.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $268.1 million, marking a year-over-year decrease of 2313.72%. This contributed to the annual value of $352.0 million for FY2024, which is 757.76% down from last year.
  • As of Q3 2025, Legend Biotech's Total Non-Current Liabilities stood at $268.1 million, which was down 2313.72% from $388.9 million recorded in Q2 2025.
  • Over the past 5 years, Legend Biotech's Total Non-Current Liabilities peaked at $388.9 million during Q2 2025, and registered a low of $262860.0 during Q1 2021.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $324.5 million (2023), whereas its average is $302.9 million.
  • In the last 5 years, Legend Biotech's Total Non-Current Liabilities skyrocketed by 14310284.56% in 2022 and then tumbled by 2313.72% in 2025.
  • Quarter analysis of 5 years shows Legend Biotech's Total Non-Current Liabilities stood at $124.3 million in 2021, then surged by 132.36% to $288.9 million in 2022, then soared by 31.83% to $380.8 million in 2023, then fell by 7.58% to $352.0 million in 2024, then fell by 23.82% to $268.1 million in 2025.
  • Its Total Non-Current Liabilities was $268.1 million in Q3 2025, compared to $388.9 million in Q2 2025 and $363.5 million in Q1 2025.